Visit AmoyDx at AACR Annual Meeting 2019 in Atlanta, USA

AmoyDx will be exhibiting at AACR Annual Meeting 2019 in Atlanta, Georgia, USA. Welcome to visit us and say hello at Booth 4260. See you there.

AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit approved by Chinese Authority

AmoyDx^® BRCA1 and BRCA2 Gene Mutation Detection Kit was approved by Chinese National Medical Products Administration (NMPA) on February 27, 2019, intended for qualitative detection of gene BRCA1 and BRCA2 mutation in patients with different cancer types  

Welcome to visit AmoyDx on 17th Congress on Targeted Anticancer Therapies (TAT) in Paris

The 17th Congress on Targeted Anticancer Therapies started in Paris on 25 February, 2019. The three-day congress will be a good opportunity to shape the future of oncology drug product development together with the world’s most renowned experts.

AmoyDx ROS1 Kit Approval in Taiwan

Recently AmoyDx ROS1 gene fusion detection kit (fluorescence PCR method) was approved by Taiwan Food and Drug Administration(TFDA).

AmoyDx® Essential NGS panel approval from Chinese authority

AmoyDx^® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell

2018 AmoyDx Distributors Annual Meeting successfully held in Shanghai

November 11, 2018 (Shanghai, China) AmoyDx Distributors Annual Meeting 2018 was held in Shanghai on November 8, 2018. 34 delegates from 19 countries gathered together to get the latest market

AmoyDx ROS1 Gene Fusions Detection Kit was Approved by South Korea MFDS as Companion Diagnostics for Pfizer's Crizotinib

Visit AmoyDx at the 19th World Conference on Lung Cancer (WCLC) 2018 in Canada

Amoy Diagnostics will be exhibiting at 19th World Conference on Lung Cancer 2018 of IASLC in Toronto, Canada. Welcome to visit us at booth 206.

Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit

Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA（National Medical Products Administration）approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.